330 related articles for article (PubMed ID: 26348402)
1. A randomized, non-inferiority trial comparing two bivalent killed, whole cell, oral cholera vaccines (Euvichol vs Shanchol) in the Philippines.
Baik YO; Choi SK; Olveda RM; Espos RA; Ligsay AD; Montellano MB; Yeam JS; Yang JS; Park JY; Kim DR; Desai SN; Singh AP; Kim IY; Kim CW; Park SN
Vaccine; 2015 Nov; 33(46):6360-5. PubMed ID: 26348402
[TBL] [Abstract][Full Text] [Related]
2. A randomized, observer-blinded, equivalence trial comparing two variations of Euvichol®, a bivalent killed whole-cell oral cholera vaccine, in healthy adults and children in the Philippines.
Russo P; Ligsay AD; Olveda R; Choi SK; Kim DR; Park JY; Park JY; Syed KA; Dey A; Kim YH; Lee SH; Kim J; Chon Y; Digilio L; Kim CW; Excler JL
Vaccine; 2018 Jul; 36(29):4317-4324. PubMed ID: 29895500
[TBL] [Abstract][Full Text] [Related]
3. Safety and immunogenicity of the Euvichol-S oral cholera vaccine for prevention of Vibrio cholerae O1 infection in Nepal: an observer-blind, active-controlled, randomised, non-inferiority, phase 3 trial.
Song KR; Chapagain RH; Tamrakar D; Shrestha R; Kanodia P; Chaudhary S; Wartel TA; Yang JS; Kim DR; Lee J; Park EL; Cho H; Lee J; Thaisrivichai P; Vemula S; Kim BM; Gupta B; Saluja T; Pansuriya RK; Ganapathy R; Baik YO; Lee YJ; Jeon S; Park Y; Her HL; Park Y; Lynch JA
Lancet Glob Health; 2024 May; 12(5):e826-e837. PubMed ID: 38614631
[TBL] [Abstract][Full Text] [Related]
4. A phase I/II study to evaluate safety, tolerability and immunogenicity of Hillchol®, an inactivated single Hikojima strain based oral cholera vaccine, in a sequentially age descending population in Bangladesh.
Chowdhury F; Ali Syed K; Akter A; Rahman Bhuiyan T; Tauheed I; Khaton F; Biswas R; Ferdous J; Al Banna H; Ross AG; Mc Millan N; Sharma T; Kanchan V; Pal Singh A; Gill D; Lebens M; Nordqvist S; Holmgren J; Clemens JD; Qadri F
Vaccine; 2021 Jul; 39(32):4450-4457. PubMed ID: 34218960
[TBL] [Abstract][Full Text] [Related]
5. Safety and immunogenicity study of a killed bivalent (O1 and O139) whole-cell oral cholera vaccine Shanchol, in Bangladeshi adults and children as young as 1 year of age.
Saha A; Chowdhury MI; Khanam F; Bhuiyan MS; Chowdhury F; Khan AI; Khan IA; Clemens J; Ali M; Cravioto A; Qadri F
Vaccine; 2011 Oct; 29(46):8285-92. PubMed ID: 21907255
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the immunogenicity and safety of Euvichol-Plus with Shanchol in healthy Indian adults and children: an open-label, randomised, multicentre, non-inferiority, parallel-group, phase 3 trial.
Shah S; Nandy RK; Sethi SS; Chavan B; Pathak S; Dutta S; Rai S; Singh C; Chayal V; Patel C; Kumar NR; Chavan AT; Chawla A; Singh A; Roy AK; Singh N; Baik YO; Lee Y; Park Y; Jeong KH; Ahmed S
Lancet Reg Health Southeast Asia; 2023 Dec; 19():100256. PubMed ID: 38076719
[TBL] [Abstract][Full Text] [Related]
7. Oral killed cholera vaccines for preventing cholera.
Saif-Ur-Rahman KM; Mamun R; Hasan M; Meiring JE; Khan MA
Cochrane Database Syst Rev; 2024 Jan; 1(1):CD014573. PubMed ID: 38197546
[TBL] [Abstract][Full Text] [Related]
8. Safety and immunogenicity of the killed bivalent (O1 and O139) whole-cell cholera vaccine in the Philippines.
Capeding MRZ; Gonzales MLAM; Dhingra MS; D'Cor NA; Midde VJ; Patnaik BN; Thollot Y; Desauziers E
Hum Vaccin Immunother; 2017 Oct; 13(10):2232-2239. PubMed ID: 28910563
[TBL] [Abstract][Full Text] [Related]
9. Safety and immunogenicity of a killed bivalent (O1 and O139) whole-cell oral cholera vaccine in adults and children in Vellore, South India.
Raghava Mohan V; Raj S; Dhingra MS; Aloysia D'Cor N; Singh AP; Saluja T; Kim DR; Midde VJ; Kim Y; Vemula S; Narla SK; Sah B; Ali M
PLoS One; 2019; 14(6):e0218033. PubMed ID: 31211792
[TBL] [Abstract][Full Text] [Related]
10. A non-inferiority trial comparing two killed, whole cell, oral cholera vaccines (Cholvax vs. Shanchol) in Dhaka, Bangladesh.
Chowdhury F; Akter A; Bhuiyan TR; Tauheed I; Teshome S; Sil A; Park JY; Chon Y; Ferdous J; Basher SR; Ahmed F; Karim M; Ahasan MM; Mia MR; Masud MMI; Khan AW; Billah M; Nahar Z; Khan I; Ross AG; Kim DR; Ashik MMR; Digilio L; Lynch J; Excler JL; Clemens JD; Qadri F
Vaccine; 2022 Jan; 40(4):640-649. PubMed ID: 34969541
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity of a killed bivalent (O1 and O139) whole cell oral cholera vaccine, Shanchol, in Haiti.
Charles RC; Hilaire IJ; Mayo-Smith LM; Teng JE; Jerome JG; Franke MF; Saha A; Yu Y; Kováč P; Calderwood SB; Ryan ET; LaRocque RC; Almazor CP; Qadri F; Ivers LC; Harris JB
PLoS Negl Trop Dis; 2014 May; 8(5):e2828. PubMed ID: 24786645
[TBL] [Abstract][Full Text] [Related]
12. Bivalent oral cholera vaccine in participants aged 1 year and older in the Dominican Republic: A phase III, single-arm, safety and immunogenicity trial.
Cordero De Los Santos L; Feris-Iglesias J; Aloysia D'Cor N; Midde VJ; Patnaik BN; Thollot Y; Rasuli A; Desauziers E
Hum Vaccin Immunother; 2018 Jun; 14(6):1403-1411. PubMed ID: 29470934
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity of a killed bivalent whole cell oral cholera vaccine in forcibly displaced Myanmar nationals in Cox's Bazar, Bangladesh.
Chowdhury F; Bhuiyan TR; Akter A; Bhuiyan MS; Khan AI; Hossain M; Tauheed I; Ahmed T; Islam S; Rafique TA; Siddique SA; Harun NB; Islam K; Clemens JD; Qadri F
PLoS Negl Trop Dis; 2020 Mar; 14(3):e0007989. PubMed ID: 32176695
[TBL] [Abstract][Full Text] [Related]
14. Induction of systemic, mucosal and memory antibody responses targeting Vibrio cholerae O1 O-specific polysaccharide (OSP) in adults following oral vaccination with an oral killed whole cell cholera vaccine in Bangladesh.
Akter A; Dash P; Aktar A; Jahan SR; Afrin S; Basher SR; Hakim A; Lisa AK; Chowdhury F; Khan AI; Xu P; Charles RC; Kelly M; Kováč P; Harris JB; Bhuiyan TR; Calderwood SB; Ryan ET; Qadri F
PLoS Negl Trop Dis; 2019 Aug; 13(8):e0007634. PubMed ID: 31369553
[TBL] [Abstract][Full Text] [Related]
15. Investigations into the safety and immunogenicity of a killed oral cholera vaccine developed in Viet Nam.
Trach DD; Cam PD; Ke NT; Rao MR; Dinh D; Hang PV; Hung NV; Canh DG; Thiem VD; Naficy A; Ivanoff B; Svennerholm AM; Holmgren J; Clemens JD
Bull World Health Organ; 2002; 80(1):2-8. PubMed ID: 11884967
[TBL] [Abstract][Full Text] [Related]
16. Development of Hillchol®, a low-cost inactivated single strain Hikojima oral cholera vaccine.
Sharma T; Joshi N; Kumar Mandyal A; Nordqvist SL; Lebens M; Kanchan V; Löfstrand M; Jeverstam F; Mainul Ahasan M; Khan I; Karim M; Muktadir H; Muktadir A; Gill D; Holmgren J
Vaccine; 2020 Nov; 38(50):7998-8009. PubMed ID: 33139137
[TBL] [Abstract][Full Text] [Related]
17. Safety and immunogenicity of a reformulated Vietnamese bivalent killed, whole-cell, oral cholera vaccine in adults.
Anh DD; Canh DG; Lopez AL; Thiem VD; Long PT; Son NH; Deen J; von Seidlein L; Carbis R; Han SH; Shin SH; Attridge S; Holmgren J; Clemens J
Vaccine; 2007 Jan; 25(6):1149-55. PubMed ID: 17055622
[TBL] [Abstract][Full Text] [Related]
18. Safety and immunogenicity of oral killed whole cell recombinant B subunit cholera vaccine in Barranquilla, Colombia.
Concha A; Giraldo A; Castañeda E; Martínez M; de la Hoz F; Rivas F; Depetris A; Svennerholm AM; Sack DA
Bull Pan Am Health Organ; 1995 Dec; 29(4):312-21. PubMed ID: 8605522
[TBL] [Abstract][Full Text] [Related]
19. A Randomized, Placebo-Controlled Trial Evaluating Safety and Immunogenicity of the Killed, Bivalent, Whole-Cell Oral Cholera Vaccine in Ethiopia.
Desai SN; Akalu Z; Teshome S; Teferi M; Yamuah L; Kim DR; Yang JS; Hussein J; Park JY; Jang MS; Mesganaw C; Taye H; Beyene D; Bedru A; Singh AP; Wierzba TF; Aseffa A
Am J Trop Med Hyg; 2015 Sep; 93(3):527-533. PubMed ID: 26078323
[TBL] [Abstract][Full Text] [Related]
20. Robust gut associated vaccine-specific antibody-secreting cell responses are detected at the mucosal surface of Bangladeshi subjects after immunization with an oral killed bivalent V. cholerae O1/O139 whole cell cholera vaccine: comparison with other mucosal and systemic responses.
Shamsuzzaman S; Ahmed T; Mannoor K; Begum YA; Bardhan PK; Sack RB; Sack DA; Svennerholm AM; Holmgren J; Qadri F
Vaccine; 2009 Feb; 27(9):1386-92. PubMed ID: 19146897
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
